.

RAISE I Chairpersons: M. Edip Gurol (Neurology, MGH/HMS)
Marc Fisher (Neurology, BIDMC/HMS)

Co-Chairs: Jin-Moo Lee (Neurology, Wash U. St-Louis), Jose G. Merino(Neurology, Georgetown U, DC)

8:15-8:27 am
UNDERSTANDING INTRACEREBRAL HEMORRHAGE RISK AND ITS RELEVANCE IN STROKE PREVENTION
Alvin S. Das (Neurology, MGH/HMS)

8:27-8:39 am
PLASMA BIOMARKERS OF STROKE RISK AND ETIOLOGY
Hooman Kamel (Neurology, Cornell)

8:39-8:51 am
COGNITION AS AN OUTCOME MEASURE IN STROKE PREVENTION TRIALS
Rebecca Gottesman (NINDS)

8:51-9:03 am
HOW TO INCORPORATE IMAGING MARKERS IN STROKE PREVENTION TRIALS
Jonathan Graff-Radford (Neurology, Mayo Clinic Rochester)

9:03-9:15 am
NOVEL TREATMENT TARGETS IN CEREBRAL SMALL VESSEL DISEASES
Steven M. Greenberg (Neurology, MGH/HMS)

9:15-10:05
DISCUSSION
Thomas Christen (Boston Scientific); Harry Reddy ALLM); Ajay Wakhloo (Neurointerventional Radiology, Lahey Hospital & Medical Center); Candice Silversides (Cardiology, University of Toronto)

.

Co-Chairs: Magdy Selim (Neurology, BIDMC/HMS),Christine M. Albert (Cardiac EP, Cedars Sinai)

10:25-10:37 am
ATRIAL FIBRILLATION MONITORING AND BURDEN
Marc Fisher (Neurology, BIDMC/HMS)

10:37-10:49 am
LEFT ATRIAL APPENDAGE: ANATOMY, FUNCTION AND ITS ROLE IN AFIB-RELATED EMBOLISM
Shadi Yaghi (Neurology, Brown University)

10:49-11:01 am
LEFT ATRIAL APPENDAGE CLOSURE FOR STROKE PREVENTION IN AFIB
Vivek Reddy (Cardiac EP, Mount Sinai, NYC)

11:01-11:13 am
ORAL ANTICOAGULANT UNDERUSE IN AF PATIENTS: PREDICTORS AND IMPLICATIONS
Jonathan Hsu (Cardiac EP, USCD, CA)

11:13-11:25 am
OUR FAILURES IN STROKE PREVENTION IN AFIB: INSIGHTS FROM THE NEURO-AFIB STUDY
M. Edip Gurol (Neurology, MGH/HMS)

11:25am -12:15pm
DISCUSSION
Larry Fine (NHLBI), Ryan Gage (ABBOTT); Kenneth Stein (Boston Scientific); Karah Neisen (Medtronic),

.

Co-Chairs: Bruce Ovbiagele (Neurology, UCSF/SFVAHCS), Joseph Broderick (Neurology, Univ. Cincinnati)

1:15-1:27 pm
PFOS AND THEIR CLOSURE: WHAT OTHER DATA ARE NEEDED?
Jeff Saver (Neurology, UCLA)

1:27-1:39 pm
SURGICAL MEASURES FOR STROKE PREVENTION: FROM LAA CLIPPING TO PROTECTIVE DEVICES
Christopher R. Ellis (Cardiology, Vanderbuilt University)

1:39-1:51 pm
ADVANCES IN PLATELET AGGREGATION INHIBITORS FOR STROKE PREVENTION
Gregory W. Albers (Neurology, Stanford Univ.)

1:51-2:03 pm
UPDATES ON LARGE VESSEL DISEASE TREATMENT: CREST-2 AND BEYOND
Larry Goldstein (U Kentucky, KY)

2:03-2:15 pm
RUNNING PRAGMATIC TRIALS & IMPLEMENTATION STUDIES IN AHA’S GWTG
Jonathan Piccini (Cardiac EP, Duke)

2:15-3:05 pm
DISCUSSION
Ahmed Elmouelhi (AtriCure), Orchid Plescia (ABBOTT), Tom Biggerstaff (Gore Medical),

.

Co-Chairs: Louise McCullough (Neurology, Univ Texas Houston), Mitch Elkind (Neurology, Columbia University)

3:25-3:37 pm
SEX AND RACE DIFFERENCES IN STROKE PREVENTION: ISSUES RELEVANT TO CLINICAL TRIALS AND PRACTICE
Anjail Sharrief (Neurology, Univ Texas Houston)

3:37-3:49 pm
NOACS BEYOND NVAF AND DVT: WHAT HAVE WE LEARNED FROM COMPASS & ESUS STUDIES
Ralph Sacco (Neurology, Univ Miami)

3:49-4:01 pm
FACTOR XI INHIBITORS
Elaine Hylek(Internal Medicine, Boston University)

4:01-4:13 pm
PCSK9 INHIBITORS FOR STROKE PREVENTION: CURRENT STATUS AND FUTURE DIRECTIONS
Seeman Chaturvedi (Neurology, University of Maryland, Baltimore, USA)

4:13-4:25 pm
REGULATORY PERSPECTIVES ON LEFT ATRIAL APPENDAGE CLOSURE DEVICES
Andrew Farb (FDA)

4:25-5:15 pm
DISCUSSION
Clinton B. Wright (NINDS), Patrice Desvigne-Nickens (NHLBI), Scott Janis (NINDS)

.

PREVENTION OF STROKE AND VASCULAR COGNITIVE IMPAIRMENT: PRIORITIES FOR NINDS
Walter Koroshetz (Director, NINDS)